List of Excipients in Branded Drug LENVIMA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eisai Inc	LENVIMA	lenvatinib	62856-704	CALCIUM CARBONATE	2036-02-26
Eisai Inc	LENVIMA	lenvatinib	62856-704	CELLULOSE, MICROCRYSTALLINE	2036-02-26
Eisai Inc	LENVIMA	lenvatinib	62856-704	FERRIC OXIDE RED	2036-02-26

Lenvima Excipient Strategy and Commercial Opportunities

Last updated: October 6, 2026

Lenvima, the brand name for lenvatinib, is a small-molecule kinase inhibitor marketed by Eisai. Its immediate-release hard capsules use a conventional solid-oral excipient system, creating a relatively accessible opportunity for generic manufacturers and excipient suppliers. The main commercial barriers are regulatory bioequivalence, active-ingredient supply, patent and exclusivity timing, combination-product positioning, and manufacturing controls rather than formulation complexity.

Lenvatinib is supplied primarily as 4 mg and 10 mg capsules in the United States. The FDA-approved product uses lenvatinib mesylate and a direct-compression or capsule-fill excipient platform based on mannitol, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, talc, calcium carbonate, and magnesium stearate. The capsule shell contains gelatin, titanium dioxide, and iron oxide colorants.[1]

What excipients are used in Lenvima capsules?

The U.S. Lenvima label identifies the following inactive ingredients:

Component	Functional role
Mannitol	Diluent and bulking agent
Microcrystalline cellulose	Diluent and compression aid
Hydroxypropyl cellulose	Binder
Low-substituted hydroxypropyl cellulose	Disintegrant
Talc	Glidant and anti-adherent
Calcium carbonate	Alkaline mineral filler and potential microenvironmental pH modifier
Magnesium stearate	Lubricant
Gelatin	Hard-capsule shell
Titanium dioxide	Opacifier and colorant
Yellow ferric oxide	Capsule-shell colorant

The formulation is commercially significant because it does not depend on a novel delivery technology, lipid system, amorphous dispersion, enteric coating, or modified-release mechanism. A generic developer can generally pursue the same immediate-release dosage form with alternative excipient grades, subject to pharmaceutical equivalence, bioequivalence, stability, and quality requirements.

Why does the Lenvima excipient system matter?

The formulation has four useful characteristics for generic development:

1. It uses widely available compendial excipients.
2. It has a relatively short excipient list.
3. It is compatible with standard capsule manufacturing.
4. It does not require a specialized release-control coating.

The most sensitive variables are likely to be powder flow, blend uniformity, capsule-fill weight, disintegration, dissolution, assay uniformity, and degradation control. Lenvatinib is administered at relatively low strengths, so content uniformity can be more challenging than bulk-dose products. The 4 mg capsule is particularly relevant because small quantities of active ingredient increase the effect of segregation and poor blend homogeneity.

What formulation strategy should a Lenvima generic use?

A conventional immediate-release hard capsule is the lowest-risk development path. The objective should be to reproduce the reference product's dissolution and exposure profile without unnecessarily replicating every inactive ingredient.

Recommended formulation architecture

A practical generic formulation can use:

• Mannitol or lactose as the principal diluent
• Microcrystalline cellulose as a secondary diluent
• Hydroxypropyl cellulose or povidone as a binder
• Crospovidone, croscarmellose sodium, or low-substituted hydroxypropyl cellulose as a disintegrant
• Colloidal silicon dioxide or talc as a flow aid
• Magnesium stearate or sodium stearyl fumarate as a lubricant
• Standard gelatin or hydroxypropyl methylcellulose capsule shells

The selection should be driven by dissolution performance, not by ingredient matching alone. A 4 mg capsule may require a premix or ordered-addition process to control active distribution. A 10 mg capsule may permit a more conventional high-shear or low-shear blending process.

Which excipient risks are most important?

Calcium carbonate

Calcium carbonate is notable because it can affect the local pH of the formulation. A generic developer should assess whether replacing it changes dissolution, chemical stability, or precipitation behavior. The ingredient may be functioning as more than a simple filler.

Magnesium stearate

Over-lubrication can slow wetting and dissolution. The risk is higher when the formulation uses extended blending times or high lubricant concentrations. Process controls should cover lubricant addition time, blending energy, and blend uniformity.

Low-substituted hydroxypropyl cellulose

Low-substituted hydroxypropyl cellulose can support rapid disintegration while maintaining capsule-fill integrity. Substitution with another disintegrant may be feasible, but the developer must demonstrate equivalent dissolution over relevant pH conditions.

Capsule shell colorants

Color matching is commercially useful but not always legally required. Capsule color can reduce dispensing errors and support product recognition. The manufacturer must also assess gelatin source, residual moisture, brittleness, shell-machine compatibility, and regional animal-origin requirements.

What FDA regulatory pathway applies to generic Lenvima?

An ANDA is the principal U.S. pathway for a conventional generic lenvatinib capsule that matches the reference listed drug in dosage form, strength, route, labeling, and active ingredient. The applicant must demonstrate pharmaceutical equivalence and bioequivalence under section 505(j) of the Federal Food, Drug, and Cosmetic Act.[2]

The main development requirements include:

• Same active ingredient, dosage form, route, and strength
• Comparable product quality and manufacturing controls
• In vitro dissolution testing
• Human pharmacokinetic bioequivalence, unless a waiver is available
• Stability data
• Container-closure qualification
• Compliance with current good manufacturing practice

An alternate dosage form, such as an oral solution, dispersible tablet, pediatric liquid, or modified-release product, would usually require a 505(b)(2) strategy rather than a standard ANDA. That route could support meaningful product differentiation but would require additional clinical, bridging, or usability evidence.

Can excipient changes trigger a 505(b)(2) application?

Not necessarily. Changes in inactive ingredients are commonly permissible in an ANDA if the product remains pharmaceutically equivalent and satisfies FDA requirements. A 505(b)(2) application becomes more relevant when the product changes:

• Dosage form
• Route of administration
• Release profile
• Dosing flexibility
• Patient population
• Administration method
• Combination configuration

A liquid lenvatinib product intended for patients unable to swallow capsules would have stronger commercial differentiation than a conventional generic capsule, but it would also carry greater formulation, stability, palatability, dose-uniformity, and regulatory risk.

When does Lenvima lose exclusivity?

Lenvima's U.S. market protection is governed by several overlapping layers:

Protection layer	Relevance
New chemical entity exclusivity	Applied to the original FDA approval, but the five-year period is no longer the principal barrier
Method-of-use patents	May protect specific indications or dosing regimens
Formulation and solid-state patents	May cover dosage forms, crystalline forms, or manufacturing characteristics
Pediatric exclusivity	May add six months to qualifying listed patents or exclusivity
Regulatory exclusivity for later indications	Can delay approval of certain ANDA labeling or indication claims
Patent-term adjustment or extension	May move expiration beyond the basic patent term

The first U.S. approval occurred in 2015 for radioiodine-refractory differentiated thyroid cancer. Later approvals expanded use to renal cell carcinoma, hepatocellular carcinoma, and advanced endometrial cancer.[3] The commercial consequence is that generic entry analysis cannot rely on a single patent expiration date.

The relevant diligence source is the FDA Orange Book, reviewed together with issued patent records, terminal disclaimers, patent-term calculations, pediatric extensions, and litigation outcomes.[4] Patent expiration dates differ by jurisdiction and may change through patent-term adjustment or litigation.

What patents protect Lenvima and its commercial uses?

Lenvatinib protection generally falls into four categories.

Compound patents

The earliest patents cover quinoline-based kinase inhibitor compounds, including lenvatinib or lenvatinib-related compounds. These patents are the primary barrier to early generic entry and are usually the most commercially important assets.

Solid-state and composition patents

Later patents may cover:

• Lenvatinib mesylate
• Crystalline forms
• Polymorphs
• Particle-size distributions
• Pharmaceutical compositions
• Specific capsule formulations
• Stability-enhancing excipient systems

A generic formulation that avoids a particular composition claim may still enter if the active-ingredient patent has expired and no enforceable formulation claim blocks approval or launch.

Method-of-use patents

Lenvatinib has multiple approved uses, including:

• Differentiated thyroid cancer
• Renal cell carcinoma in combination with everolimus
• Unresectable hepatocellular carcinoma
• Advanced endometrial carcinoma in combination with pembrolizumab

Method-of-use patents can support carve-out strategies. An ANDA applicant may seek approval for non-patented indications while omitting protected uses from its labeling, subject to the scope of the listed patent and FDA requirements.

Manufacturing patents

Manufacturing patents may cover synthesis intermediates, purification, salt formation, crystallization, or control of impurities. These patents are particularly relevant for API suppliers. A finished-dose manufacturer can avoid some manufacturing claims by purchasing API from an independent supplier, but commercial supply agreements must allocate infringement, indemnity, and freedom-to-operate risk.

Are there Paragraph IV challenges to Lenvima?

Paragraph IV exposure depends on the patents listed in the Orange Book at the time of ANDA filing. A generic applicant can certify that an Orange Book patent is invalid, unenforceable, or will not be infringed. The brand owner may then bring patent litigation, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework.[5]

The most likely Paragraph IV targets are:

• Expiring compound patents
• Formulation patents with narrow claim scope
• Use patents that can be addressed through a label carve-out
• Patents with expiration dates materially later than the basic compound patent

A first substantially complete Paragraph IV filing may receive 180-day generic exclusivity if statutory conditions are met. That exclusivity can materially increase the value of an early filing, particularly for a high-priced oncology product.

What commercial opportunities exist for Lenvima excipients?

The excipient opportunity is larger than direct sales into the reference product. It includes generic supply, formulation services, quality-by-design support, specialty capsule shells, and differentiated dosage forms.

Generic capsule supply

The largest near-term opportunity is supplying excipients to ANDA manufacturers. Demand would center on:

• Pharmaceutical-grade mannitol
• Microcrystalline cellulose
• Hydroxypropyl cellulose
• Low-substituted hydroxypropyl cellulose
• Calcium carbonate with controlled particle characteristics
• Talc and magnesium stearate
• Gelatin or vegetarian capsule shells

Suppliers with global regulatory packages, multiple manufacturing sites, and reliable supply continuity will have an advantage. Oncology products are often subject to tighter procurement scrutiny because shortages can affect treatment continuity.

Formulation development services

Contract development organizations can offer:

• Excipient compatibility screening
• Design of experiments for 4 mg and 10 mg strengths
• Dissolution matching
• Blend-uniformity optimization
• Capsule-fill process development
• Stability and extractables/leachables programs
• Scale-up and technology transfer

A formulation that uses common excipients but has robust manufacturing tolerances can reduce regulatory risk and lower cost of goods.

Oral liquid and pediatric formulations

A liquid formulation could target patients with dysphagia, feeding tubes, or difficulty swallowing capsules. The main technical challenges are:

• Lenvatinib solubility
• Chemical stability in aqueous or semi-aqueous media
• Dose uniformity after storage
• Palatability
• Adsorption to administration devices
• Compatibility with enteral feeding tubes
• Microbiological preservation

A nonaqueous suspension or powder-for-reconstitution system may be more practical than a ready-to-use aqueous solution. Such a product would require a clear clinical and regulatory value proposition.

Fixed-dose and co-packaged oncology products

Lenvatinib is used with everolimus for renal cell carcinoma and with pembrolizumab for endometrial carcinoma. A fixed-dose combination would be difficult because of differing dose requirements, stability profiles, and intellectual-property positions. A co-packaged product or coordinated adherence kit may be more feasible, although it would still require regulatory and commercial justification.

Specialty packaging

Commercial opportunities include:

• Unit-dose blister packaging
• Child-resistant packaging
• Calendarized adherence packs
• Moisture-protective containers
• Low-volume pharmacy packaging
• Hospital and specialty-pharmacy dispensing formats

Packaging does not replace formulation differentiation, but it can improve handling and reduce medication errors in chronic oncology treatment.

How strong is the Lenvima formulation patent estate?

The formulation estate appears less difficult to design around than estates based on liposomes, injectables, controlled release, or complex biologics. The reference product uses familiar excipients and a conventional capsule. That supports a moderate formulation barrier.

The overall estate can still be commercially strong because compound, use, regulatory, and supply-chain protections operate together. A generic applicant must evaluate the complete claim set rather than only the inactive ingredients in the FDA label.

Estate component	Commercial strength
Core small-molecule compound	High importance
Conventional capsule formulation	Moderate design-around potential
Method-of-use claims	Relevant for indication-specific launches
API manufacturing claims	Potentially significant
Combination-use positioning	Commercially important, legally complex
Biosimilar protection	Not applicable
Excipient exclusivity	Generally low unless tied to a claimed composition

Is Lenvima exposed to biosimilar competition?

No. Lenvatinib is a chemically synthesized small molecule, not a biologic. Competition would come through generic small-molecule pathways, including ANDAs and potentially 505(b)(2) products. Biosimilar provisions under the Biologics Price Competition and Innovation Act do not apply.

How does Lenvima compare with other oral oncology products?

Lenvima's conventional capsule platform creates a lower formulation barrier than products requiring complex delivery systems. Its commercial profile is different from biologic oncology products, where biosimilar development depends on analytical comparability, clinical bridging, and manufacturing complexity.

Compared with other oral kinase inhibitors, Lenvima has a broader combination-use profile and multiple tumor indications. That can increase revenue exposure to label carve-outs and create value for generic companies able to launch selectively by indication.

What generic launch scenarios exist for Lenvima?

Three launch scenarios are commercially plausible:

1. Single-generic entry after core patent expiry.
   This is the standard scenario. Price erosion would depend on the number of approved suppliers and the strength of specialty-pharmacy demand.

2. First-filer or limited-competition entry.
   An early Paragraph IV challenge could create a period of limited competition, particularly if litigation resolves before multiple ANDAs are approved.

3. Indication-limited launch.
   A generic could enter with labeling that omits a patented method of use. This approach can reduce litigation exposure but may limit contracting, oncology guideline positioning, and physician adoption.

For the brand, revenue exposure is concentrated in the continued use of Lenvima across several cancers and in combination regimens. For generic entrants, the opportunity depends on launch timing, API cost, payer substitution, specialty distribution, and the ability to maintain uninterrupted supply.

Key Takeaways

• Lenvima uses a conventional immediate-release hard-capsule formulation.
• The principal excipients are mannitol, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, talc, calcium carbonate, and magnesium stearate.
• A generic capsule is likely to be more accessible than a liquid or modified-release product.
• Calcium carbonate, lubricant level, blend uniformity, and low-dose content uniformity are important development variables.
• The principal U.S. route for a conventional generic is an ANDA.
• Alternate dosage forms would likely require a 505(b)(2) strategy.
• Lenvatinib has no biosimilar pathway because it is a small molecule.
• Patent risk extends beyond the active compound to methods of use, formulation, solid state, and manufacturing.
• The most attractive excipient opportunities are generic supply, formulation development, pediatric or dysphagia products, and specialty packaging.
• Exact launch timing requires a current Orange Book review and claim-by-claim patent analysis.

FAQs About Lenvima Excipients and Generic Competition

What is the main excipient opportunity for lenvatinib?

The main opportunity is supplying pharmaceutical-grade excipients for generic 4 mg and 10 mg immediate-release capsules. Development services for blend uniformity, dissolution matching, and scale-up are also commercially relevant.

Can Lenvima be reformulated as an oral liquid?

Potentially, but the product would face solubility, stability, palatability, dose-uniformity, and regulatory challenges. A suspension or powder-for-reconstitution may be more practical than a simple aqueous solution.

Does Lenvima require a specialized capsule shell?

The reference product uses a conventional hard capsule with colorants. Generic manufacturers can generally evaluate gelatin or vegetarian shells, subject to compatibility, moisture, appearance, and regulatory requirements.

Can a generic lenvatinib product omit certain cancer indications?

A generic applicant may be able to use a section 8 labeling carve-out for a patented method of use. The feasibility depends on the exact patent claims, FDA-listed indications, and the proposed labeling.

Are Lenvima's inactive ingredients themselves protected by patent?

Individual common excipients are generally not exclusive. Legal risk may arise from a patent claiming a specific composition, ratio, particle-size profile, manufacturing process, or stability result rather than from the use of an excipient in isolation.

References

1. U.S. Food and Drug Administration. (2024). LENVIMA (lenvatinib mesylate) capsules: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process.
3. U.S. Food and Drug Administration. (2015-2021). Lenvima approval history and supplemental approvals.
4. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).